Clinical Genomics Pty Ltd

North Ryde, Australia

Clinical Genomics Pty Ltd

North Ryde, Australia
SEARCH FILTERS
Time filter
Source Type

Patent
Quest Diagnostics, Clinical Genomics Pty. Ltd., Pedersen, Lapointe and Baker | Date: 2017-04-12

Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.


Patent
Clinical Genomics Pty. Ltd. | Date: 2017-07-12

Provided is a test device for testing an analyte in a collected sample comprising: an enclosure having at least one sample receiving port for receiving the sample; a test strip located within the enclosure, the test strip containing at least one reagent for detecting the analyte and for providing an indication showing a test result for the sample, the enclosure including a detection arrangement for allowing detection of the indication of the test strip; a sample receiving matrix positioned behind the at least one sample receiving port and having a defined saturation capacity, the sample receiving matrix being impregnated with reagents for pre-treatment of the sample and being in liquid conductive communication with the test strip. Also provided is a method for use of said test device comprising: delivering one or more samples to the at least one sample receiving port to saturate the sample receiving matrix such that a quantified amount of the sample is transferred to the test strip and an indication of the test result is effected.


Patent
Clinical Genomics Pty. Ltd. and Csiro | Date: 2016-12-16

The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.


Patent
Clinical Genomics Pty. Ltd. | Date: 2017-04-12

The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and RNA methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.


Patent
Clinical Genomics Pty Ltd | Date: 2015-06-01

The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.


Patent
Clinical Genomics Pty Ltd and Csiro | Date: 2016-06-22

A method of screening for the onset or predisposition to the onset of a large intestine neoplasm or monitoring the progress of a neoplasm in an individual, said method comprising assessing the methylation status of a DNA region selected from: the region defined by Hg19 coordinates chr7:50344378..50472799 and 2kb upstream of the transcription start site; or the gene region, including 2kb upstream, of IKZF1 in a biological sample from said individual wherein a higher level of methylation of the DNA regions of group (i) and/or (ii) relative to control levels is indicative of a large intestine neoplasm or a predisposition to the onset of a large intestine neoplastic state.


Patent
Clinical Genomics Pty. Ltd. and Csiro | Date: 2014-11-13

The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.


Patent
Clinical Genomics Pty. Ltd. and Csiro | Date: 2015-08-12

The present invention relates generally to a nucleic acid molecule, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenomas and adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a large intestine neoplasm by screening for modulation in the expression profile of said nucleic acid molecule markers.


Patent
Clinical Genomics Pty Ltd and Csiro | Date: 2016-06-22

A method of screening for the onset or predisposition to the onset of a large intestine neoplasm or monitoring the progress of a neoplasm in an individual, said method comprising assessing the methylation status of a DNA region selected from: the region defined by Hg19 coordinates chr12:24964278..25102308 and 2kb upstream of the transcription start site, or the gene region, including 2kb upstream, of BCAT1 in a biological sample from said individual wherein a higher level of methylation of the DNA regions of group (i) and/or (ii) relative to control levels is indicative of a large intestine neoplasm or a predisposition to the onset of a large intestine neoplastic state.


Patent
Clinical Genomics Pty Ltd and Csiro | Date: 2016-08-17

The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas, Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.

Loading Clinical Genomics Pty Ltd collaborators
Loading Clinical Genomics Pty Ltd collaborators